Evaluation of new possibilities for individualization in reproductive medicine

PRESS RELEASE

Merck and VivoSensMedical evaluate new possibilities for individualizing reproductive medicine

Leipzig/Darmstadt, 10 March 2021. VivoSensMedical GmbH and Merck KGaA, a leading science and technology company, intend to explore potential for product development to individualize fertility treatments in a joint project. The two companies aim to identify algorithms as well as digital methods and products that can create new possibilities for reproductive medicine treatments, with the option of later developing these together.

VivoSensMedical GmbH is a young medical technology company from Leipzig that, together with reproductive medicine specialist Prof. Henry Alexander, has developed OvulaRing. OvulaRing is a patented and Europe-wide approved medical device that captures the female cycle in full based on high-resolution core body temperature measurements and, on this basis, provides insights into individual cycle health. With more than 15,000 fully recorded cycles, VivoSensMedical has the world’s largest database of continuously measured core body temperature.

Henry Alexander is one of the pioneers of in vitro fertilisation in Germany and has more than 40 years of experience in medical research and practice. “Slowly but surely, medicine is realising that therapy should be as individual as the person themselves. Every woman has an individual cycle pattern, which we can capture using OvulaRing’s vaginal ring sensor. I see great potential in taking these patterns into account in reproductive medicine treatments and tailoring them to individual cycle biology.”